Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial.
Nanni O, Amadori D, De Censi A, Rocca A, Freschi A, Bologna A, Gianni L, Rosetti F, Amaducci L, Cavanna L, Foca F, Sarti S, Serra P, Valmorri L, Bruzzi P, Corradengo D, Gennari A; MYME investigators. Nanni O, et al. Among authors: freschi a. Breast Cancer Res Treat. 2019 Apr;174(2):433-442. doi: 10.1007/s10549-018-05070-2. Epub 2018 Dec 7. Breast Cancer Res Treat. 2019. PMID: 30536182 Free article. Clinical Trial.
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, Lo Re G, Nortilli R, Brugnara S, Vitali P, Nanni O; Italian Melanoma Intergroup. Ridolfi R, et al. Among authors: freschi a. J Clin Oncol. 2002 Mar 15;20(6):1600-7. doi: 10.1200/JCO.2002.20.6.1600. J Clin Oncol. 2002. PMID: 11896110 Clinical Trial.
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma.
Guida M, Riccobon A, Biasco G, Ravaioli A, Casamassima A, Freschi A, Palma MD, Galligioni E, Nortilli R, Chiarion-Sileni V, Picozzo J, Romanini A, Nanni O, Ridolfi R; Italian Melanoma Intergroup (IMI). Guida M, et al. Among authors: freschi a. Melanoma Res. 2006 Aug;16(4):317-23. doi: 10.1097/01.cmr.0000200491.00841.5f. Melanoma Res. 2006. PMID: 16845327 Clinical Trial.
Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L, Fiorentini G, Guida M, Michiara M, Freschi A, Aitini E, Ballardini M, Bichisao E, Ridolfi R; Italian Melanoma Intergroup. Ridolfi L, et al. Among authors: freschi a. Melanoma Res. 2009 Apr;19(2):100-5. doi: 10.1097/CMR.0b013e328328f7ec. Melanoma Res. 2009. PMID: 19262411 Clinical Trial.
Fertility concerns, preservation strategies and quality of life in young women with breast cancer: Baseline results from an ongoing prospective cohort study in selected European Centers.
Ruggeri M, Pagan E, Bagnardi V, Bianco N, Gallerani E, Buser K, Giordano M, Gianni L, Rabaglio M, Freschi A, Cretella E, Clerico M, Farolfi A, Simoncini E, Ciccarese M, Rauch D, Ramello M, Glaus A, Berardi R, Pellanda AF, Ribi K, Gelber S, Partridge AH, Goldhirsch A, Pagani O. Ruggeri M, et al. Among authors: freschi a. Breast. 2019 Oct;47:85-92. doi: 10.1016/j.breast.2019.07.001. Epub 2019 Jul 10. Breast. 2019. PMID: 31362134
Long-term survival in patients with metastatic renal cell carcinoma treated with continuous intravenous infusion of recombinant interleukin-2: the experience of a single institution.
Libra M, Talamini R, Crivellari D, Buonadonna A, Freschi A, Stefanovski P, Berretta M, De Cicco M, Balestreri L, Merlo A, Volpe R, Galligioni E, Sorio R. Libra M, et al. Among authors: freschi a. Tumori. 2003 Jul-Aug;89(4):400-4. doi: 10.1177/030089160308900410. Tumori. 2003. PMID: 14606643
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland.
Ribi K, Pagan E, Sala I, Ruggeri M, Bianco N, Bucci EO, Graffeo R, Borner M, Giordano M, Gianni L, Rabaglio M, Freschi A, Cretella E, Seles E, Farolfi A, Simoncini E, Ciccarese M, Rauch D, Favaretto A, Glaus A, Berardi R, Franzetti-Pellanda A, Bagnardi V, Gelber S, Partridge AH, Goldhirsch A, Pagani O. Ribi K, et al. Among authors: freschi a. J Cancer Surviv. 2023 Dec;17(6):1847-1858. doi: 10.1007/s11764-022-01222-y. Epub 2022 Jun 10. J Cancer Surviv. 2023. PMID: 35689003
48 results